FY2026 Earnings Estimate for IDEAYA Biosciences, Inc. Issued By Capital One Financial (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Investment analysts at Capital One Financial reduced their FY2026 earnings per share estimates for shares of IDEAYA Biosciences in a note issued to investors on Monday, July 8th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings of ($2.58) per share for the year, down from their prior estimate of ($2.17). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.37) per share. Capital One Financial also issued estimates for IDEAYA Biosciences’ FY2027 earnings at ($1.16) EPS and FY2028 earnings at $3.02 EPS.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. IDEAYA Biosciences’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.49) EPS.

Several other research firms have also issued reports on IDYA. Mizuho started coverage on shares of IDEAYA Biosciences in a research note on Monday, July 8th. They set an “outperform” rating and a $50.00 target price on the stock. Citigroup increased their price target on IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. BTIG Research boosted their price objective on IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group decreased their target price on IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $65.00 to $69.00 and gave the stock an “overweight” rating in a report on Friday. Fourteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $53.08.

IDEAYA Biosciences Trading Up 1.0 %

Shares of NASDAQ:IDYA opened at $40.00 on Thursday. IDEAYA Biosciences has a 12-month low of $20.90 and a 12-month high of $47.74. The business has a 50 day moving average of $38.29 and a two-hundred day moving average of $40.74. The company has a market capitalization of $3.03 billion, a PE ratio of -19.90 and a beta of 0.86.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors have recently bought and sold shares of IDYA. Covestor Ltd increased its holdings in shares of IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares during the last quarter. Comerica Bank increased its stake in IDEAYA Biosciences by 723.5% during the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock worth $66,000 after acquiring an additional 1,324 shares during the last quarter. JTC Employer Solutions Trustee Ltd purchased a new stake in IDEAYA Biosciences in the first quarter valued at $67,000. AJOVista LLC acquired a new position in shares of IDEAYA Biosciences in the 4th quarter valued at $99,000. Finally, SG Americas Securities LLC purchased a new position in shares of IDEAYA Biosciences during the 1st quarter worth $101,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 56,711 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $41.61, for a total value of $2,359,744.71. Following the transaction, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at approximately $28,206,878.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Yujiro S. Hata sold 56,711 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total value of $2,359,744.71. Following the completion of the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $28,206,878.07. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Yujiro S. Hata sold 34,433 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $41.81, for a total value of $1,439,643.73. Following the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,342,455.47. The disclosure for this sale can be found here. In the last quarter, insiders sold 119,644 shares of company stock worth $4,832,228. Insiders own 3.50% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.